Standardizace PET/CT u pacientů s mnohočetným myelomem – Společné doporučení České myelomové skupiny a České společnosti nukleární medicíny

Česká verze

Authors: M. Havel ^1*; T. Jelínek ^2,3*; L. Pour ⁴; M. Štork ⁴; J. Minařík ⁵; A. Jungová ⁶; I. Špička ⁷; P. Pavlíček ⁸; J. Radocha ⁹; V. Maisnar ⁹; M. Wróbel ¹⁰; M. Sýkora ¹¹; J. Ullrychová ¹²; L. Muroňová ^2,3; E. Krčálová ¹³; E. Buriánková ¹⁴; L. Henzlová ¹⁴; G. Havlová ¹; D. Zogala ¹⁵; Hm R. Hájek ^{2,3 *}; Dílem Se Na Této Práci Podíleli Stejným Jt; autory. Prvními Jejími Jsou
Authors place of work: Klinika nukleární medicíny LF OU a FN Ostrava ¹; Klinika hematoonkologie, FN Ostrava ²; Klinika hematoonkologie, LF OU, Ostrava ³; Interní hematologická a onkologická klinika LF MU a FN Brno ⁴; Hemato-onkologická klinika LF UP a FN Olomouc ⁵; Hematologicko-onkologické oddělení, FN Plzeň ⁶; I. interní klinika – klinika hematologie 1. LF UK a VFN v Praze ⁷; Hematologická klinika 3. LF UK a FNKV, Praha ⁸; IV. interní hematologická klinika LF UK a FN Hradec Králové ⁹; Hematologické oddělení, Onkologické centrum Nový Jičín ¹⁰; Oddělení klinické hematologie, Nemocnice České Budějovice ¹¹; Oddělení klinické hematologie, Masarykova nemocnice Ústí nad Labem ¹²; Oddělení nukleární medicíny LF UK a FN Hradec Králové ¹³; Klinika nukleární medicíny LF UP a FN Olomouc ¹⁴; Ústav nukleární medicíny, VFN v Praze ¹⁵
Published in the journal: Transfuze Hematol. dnes,29, 2023, No. 2, p. 148-152.
Category: Doporučené postupy
doi: https://doi.org/10.48095/cctahd2023prolekare.cz9

Summary

Multiple myeloma is a blood cancer characterized by proliferation of clonal plasma cells in the bone marrow and the presence of paraprotein in the serum and/or urine. In recent years, whole-body positron emission tomography (PET) imaging combined with computed tomography (PET/CT) has become a preferred imaging technique for diagnosis and treatment. It has the benefit of detecting metabolically active characteristic focuses and good detection of extramedullary and para-medullary lesions. The following text presents the joint standpoint of the representatives of the Czech Society of Nuclear Medicine ČLS JEP (CSNM ČLS JEP) and the Czech Myeloma Group (CMG) regarding PET/CT examination per se as well as its evaluation and reporting. The aim is to standardize the methodology of PET/CT examination across the Czech Republic, which will be clear and simple to understand.

Keywords:

Multiple myeloma – 18F-PET/CT – evaluation of treatment response – complete metabolic response – extramedullary lesions – para-medullary lesions

Zdroje

1. Moulopoulos LA, Koutoulidis V, Hillengass J, et al. Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group. Blood Cancer J. 2018; 8 (10): 95.

2. Cavo M, Terpos E, Nanni C, et al. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017; 18 (4): e206–e217.

3. Kumar S, Glazebrook KN, Broski SM. Flude- oxyglucose F 18 PET/computed tomography evaluation of therapeutic response in multiple myeloma. PET Clinics. 2019; 14 (3): 391–403.

4. Nanni C, Zamagni E. Fluorodeoxyglucose-PET/computed tomography as a predictor of prognosis in multiple myeloma. PET Clinics. 2019; 14 (3): 383–389.

5. Seval GC, Ozkan E, Beksac M. PET with fluorodeoxyglucose F 18/computed tomography as a staging tool in multiple myeloma. PET Clinics. 2019; 14 (3): 369–381.

6. Zamagni E, Nanni C, Patriarca F, et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica. 2007; 92 (1): 50–55.

7. Muronova L, Havel M, Popkova T, Plonkova H, Hajek R, Jelinek T. Prognostic value of PET/CT performed day +100 post autologous stem cell transplantation in multiple myeloma: real-world single center experience. Blood. 2020; 136 (Suppl 1): 6–7.

8. Sevcikova S, Minarik J, Stork M, Jelinek T, Pour L, Hajek R. Extramedullary disease in multiple myeloma – controversies and future directions. Blood Rev. 2019; 36: 32–39.

9. Jelinek T, Zihala D, Sevcikova T, et al. Pathogenesis of extramedullary multiple myeloma: from resistance to identification of novel therapeutic targets. Blood. 2021; 138 (Suppl 1): 2680.

10. Jelinek T, Sevcikova T, Zihala D, et al. Limited efficacy of daratumumab in multiple myeloma with extramedullary disease. Leukemia. 2022; 36 (1): 288–291.

11. Standardy zdravotní péče – „Národní radiologické standardy – nukleární medicína“. Soubor doporučení a návod pro tvorbu místních radiologických postupů (standardů) na diagnostických a terapeutických pracovištích nukleární medicíny v České republice. Věstník Ministerstva zdravotnictví České republiky. 2016; 2016 (2/2016): 203–364.

12. Boellaard R, Delgado-Bolton R, Oyen WJG, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nuclear Med Molec Imaging. 2015; 42 (2): 328–354.

13. Zamagni E, Nanni C, Dozza L, et al. Standardization of 18 F-FDG–PET/CT according to Deauville criteria for metabolic complete response definition in newly diagnosed multiple myeloma. J Clin Oncol. 2021; 39 (2): 116–125.

14. Adam Z, Bolcak K, Stanicek J, et al. Fluorodeoxyglucose positron emission tomography in multiple myeloma, solitary plasmocytoma and monoclonal gammapathy of unknown significance. Neoplasma. 2007; 54 (6): 536–540.

15. Jelinek T, Bezdekova R, Zihala D, et al. More than 2% of circulating tumor plasma cells defines plasma cell leukemia–like multiple myeloma. J Clin Oncol. 2023; 41 (7): 1383–1392.

16. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; 17 (8): e328–e346.